Related Experiment Videos
New directions in heart failure management
1Denver Health Medical Center, Colo., USA.
Insights
Heart failure affects millions, leading to frequent hospitalizations. New management strategies focus on blocking neurohormones like angiotensin II to improve heart function and reduce hospital admissions.
Area of Science:
- Cardiology
- Internal Medicine
Background:
- Heart failure affects approximately 4.8 million Americans, causing 800,000-900,000 annual hospital admissions.
- Effective primary care management is crucial for reducing mortality and hospitalizations.
- Neurohormones, including angiotensin II and aldosterone, significantly contribute to heart failure progression.
Purpose of the Study:
- To discuss current heart failure management options.
- To highlight strategies that target neurohormonal pathways.
- To review methods that improve systolic function by retarding left ventricular remodeling.
Main Methods:
- Review of current medical literature on heart failure management.
- Focus on pharmacological interventions targeting the renin-angiotensin-aldosterone system.
- Discussion of therapies aimed at mitigating left ventricular remodeling.
Main Results:
- Angiotensin-converting enzyme inhibitors and similar drugs blocking neurohormones are beneficial.
- Management strategies can retard left ventricular remodeling.
- Improved systolic function is achievable over time with appropriate treatment.
Conclusions:
- Targeting neurohormonal pathways is key in heart failure management.
- Primary care plays a vital role in optimizing patient outcomes.
- Current treatments can improve heart function and reduce hospitalization rates.
Abstract:
Approximately 4.8 million Americans are afflicted with heart failure; this accounts for 800,000 to 900,000 hospital admissions annually. Astute management in the primary care setting is essential for decreasing mortality and minimizing the risk for hospitalization. Although heart failure was initially viewed as a hemodynamic disorder, current evidence overwhelmingly supports that neurohormones, such as angiotensin II and aldosterone, contribute significantly to disease progression. The benefits of angiotensin-converting enzyme inhibitors and other drugs that block these substances are well established. This article discusses current management options that retard left ventricular remodeling to improve systolic function over time.